# ClinicalTrials.gov record NCT04822181

> PeptideScanner retained ClinicalTrials.gov record NCT04822181 at 2026-07-30T16:19:03.054Z. Its registry update date was 2026-06-29, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct04822181-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-07-31
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04822181-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04822181-semaglutide-v1.json
- Content SHA-256: `6cac1a16a8160c9b74cf2e8b18c5f6f11827370f8c655d28f92979b2c4c9f8d3`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT04822181 ([`ctg-observation-nct04822181-2026-06-29-977c9e099af0`](#source-ctg-observation-nct04822181-2026-06-29-977c9e099af0))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04822181 at 2026-07-30T16:19:03.054Z. Its registry update date was 2026-06-29, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04822181-2026-06-29-977c9e099af0`](#source-ctg-observation-nct04822181-2026-06-29-977c9e099af0))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04822181 at 2026-07-30T16:19:03.054Z. Its registry update date was 2026-06-29, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04822181-2026-06-29-977c9e099af0`](#source-ctg-observation-nct04822181-2026-06-29-977c9e099af0))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04822181-2026-06-29-977c9e099af0`](#source-ctg-observation-nct04822181-2026-06-29-977c9e099af0))

## Sources

<a id="source-ctg-observation-nct04822181-2026-06-29-977c9e099af0"></a>
- **ClinicalTrials.gov record NCT04822181 · retained source version 2026-06-29:977c9e099af0f79d521f9e2bdccbdca3b23c40e3c70adcca7dd056dc358ccb82** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04822181) (`ctg-observation-nct04822181-2026-06-29-977c9e099af0`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04822181." Version 1, published 2026-07-31. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04822181-semaglutide-v1.json SHA-256: 6cac1a16a8160c9b74cf2e8b18c5f6f11827370f8c655d28f92979b2c4c9f8d3.